Abstract
B cell chronic lymphocytic leukemia (B-CLL) cannot be cured with conventional chemotherapy. This clinical enigma appears to be at least partially due to the fact that B-CLL cells are resistant to programmed cell death (apoptosis) and that they are arrested in G0/G1 phase of the cell cycle. The reasons for the dysregulation of these two key cellular events in B-CLL are unclear. The present study aimed at determining correlations between the expression levels of proteins regulating apoptosis, cell cycle and DNA repair in B-CLL cells and normal B cells. In addition, the differential sensitivity of B-CLL cells to drug-induced apoptosis was quantified. We show that in B-CLL cells levels of the death-suppressor Bcl-2 correlated positively with those of the pro-apoptotic protein Bax and of the cyclin-dependent kinase (cdk) inhibitor p27Kip1. In B-CLL cells levels of the anti-apoptotic Bcl-xL showed a positive correlation with levels of the 80 kDa regulatory component (Ku80) of the DNA-dependent protein kinase that is involved in DNA double-stranded break repair. These correlations were not detected in normal B cells. The sensitivity of leukemic cells to FLUD but not to ADM, CPM or to DEX was reduced in pre-treated patients. These data support the hypothesis that in B-CLL cells death-modulators and molecules modulating cell cycle and DNA repair are regulated in a coordinated manner.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Byrd JC, Rai KR, Sausville EA, Grever MR . Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals Semin Oncol 1998 25: 65–74
Rowan S, Fisher DE . Mechanisms of apoptotic cell death Leukemia 1997 11: 457–465
Reed JC . Molecular biology of chronic lymphocytic leukemia Semin Oncol 1998 25: 11–18
Reed JC . Double identity for proteins of the Bcl-2 family Nature 1997 387: 773–776
Tsujimoto Y, Cossman J, Jaffe E, Croce C . Involvement of the bcl-2 gene in human follicular lymphoma Science 1985 228: 1440–1443
Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC . bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia Blood 1993 82: 1820–1828
Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang H-G, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC . Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses Blood 1998 91: 3379–3389
Bromidge TJ, Turner DL, Howe SJ, Johnson SA, Rule SAJ . In vitro chemosensitivity of chronic lymphocytic leukemia to purine analogues – correlation with clinical course Leukemia 1998 12: 1230–1235
Sherr CJ . G1 phase progression: cycling on cue (see comments) Cell 1994 79: 551–555
Wolowiec D, Benchaib M, Pernas P, Deviller P, Souchier C, Rimokh R, Felman P, Bryon PA, Ffrench M . Expression of cell cycle regulatory proteins in chronic lymphocytic leukemias. Comparison with non-Hodgkin's lymphomas and non-neoplastic lymphoid tissue Leukemia 1995 9: 1382–1388
Delmer A, Ajchenbaum Cymbalista F, Tang R, Ramond S, Faussat AM, Marie JP, Zittoun R . Overexpression of cyclin D2 in chronic B-cell malignancies Blood 1995 85: 2870–2876
Reeves WH . Use of monoclonal antibodies for the characterization of novel DNA-binding proteins recognized by human autoimmune sera J Exp Med 1985 161: 18–39
Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR . National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment Blood 1996 87: 4990–4997
Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH . Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis Blood 1994 84: 1415–1420
Ormerod MG . The study of apoptotic cells by flow cytometry Leukemia 1998 12: 1013–1025
Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F . Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis) Cytometry 1997 27: 1–20
Vermes I, Haanen C, Steffens Nakken H, Reutelingsperger C . A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V J Immunol Meth 1995 184: 39–51
Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR . Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl J Exp Med 1995 182: 1545–1556
Pepper C, Hoy T, Bentley DP . Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance Br J Cancer 1997 76: 935–938
McConkey DJ, Chandra J, Wright S, Plunkett W, McDonnell TJ, Reed JC, Keating M . Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX J Immunol 1996 156: 2624–2630
Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC . Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma Cancer Res 1995 55: 4471–4478
Krajewski S, Thor AD, Edgerton SM, Moore DHN, Krajewska M, Reed JC . Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers Clin Cancer Res 1997 3: 199–208
Miyashita T, Kitada S, Krajewski S, Horne WA, Delia D, Reed JC . Overexpression of the Bcl-2 protein increases the half-life of p21Bax J Biol Chem 1995 270: 26049–26052
Chen J, Flannery JG, LaVail MM, Steinberg RH, Xu J, Simon MI . bcl-2 overexpression reduces apoptotic photoreceptor cell death in three different retinal degenerations Proc Natl Acad Sci USA 1996 93: 7042–7047
Middleton G, Nunez G, Davies AM . Bax promotes neuronal survival and antagonises the survival effects of neurotrophic factors Development 1996 122: 695–701
Meijerink JPP, Mensink EJBM, Wang K, Sedlak TW, Slöetjes AW, de Witte T, Waksman G, Korsmeyer SJ . Hematopoietic malignancies demonstrated loss-of-function mutations of BAX Blood 1998 91: 2991–2997
Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchenbaum Cymbalista F . Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia Blood 1998 91: 4694–4700
Gil Gomez G, Berns A, Brady HJ . A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis EMBO J 1998 17: 7209–7218
Linette GP, Li Y, Roth K, Korsmeyer SJ . Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation Proc Natl Acad Sci USA 1996 93: 9545–9552
Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T . p27 expression and gastric carcinoma Nature Med 1997 6: 593
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM . Decreased levels of the cell-cycle inhibitor p27Kipl protein: prognostic implications in primary breast cancer (see comments) Nature Med 1997 3: 227–230
Broome HE, Dargan CM, Krajewski S, Reed JC . Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal J Immunol 1995 155: 2311–2317
Tuscano JM, Druey KM, Riva A, Pena J, Thompson CB, Kehrl JH . Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center Blood 1996 88: 1359–1364
Ghia P, Boussiotis VA, Schultze JL, Cardoso AA, Dorfman DM, Gribben JG, Freedman AS, Nadler LM . Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival Blood 1998 91: 244–251
Nussenzweig A, Sokol K, Burgman P, Li L, Li GC . Hypersensitivity of Ku80-deficient cell lines and mice to DNA damage: the effects of ionizing radiation on growth, survival and development Proc Natl Acad Sci USA 1997 94: 13588–13593
Ajmani AK, Satoh M, Reap E, Cohen PL, Reeves WH . Absence of autoantigen Ku in mature human neutrophils and human promyelocytic leukemia line (HL-60) cells and lymphocytes undergoing apoptosis J Exp Med 1995 181: 2049–2058
Le Romancer M, Cosulich SC, Jackson SP, Clarke PR . Cleavage and inactivation of DNA-dependent protein kinase catalytic subunit during apoptosis in Xenopus egg extracts J Cell Sci 1996 109: 3121–3127
Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V, Estey E, Keating MJ . Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies Semin Oncol 1993 20: 2–12
Bellosillo B, Colomer D, Montserrat E, Pons G, Gil J . Mitoxantrone induces apoptosis in B cell chronic lymphocytic leumia cells and it apoptotic effect is increased by fludarabine Blood 1997 20: (Suppl. 1) 201b
Silber R, Degar B, Costin D, Newcomb EW, Mani M, Rosenberg CR, Morse L, Drygas JC, Canellakis ZN, Potmesil M . Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs Blood 1994 84: 3440–3446
Bosanquet AG, Bell PB . Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia Blood 1996 87: 1962–1971
Morabito F, Callea I, Rodino A, Messina G, Callea V, Iacopino P, Nobile F, Brugiatelli M . Modulation of purine analogs- and chlorambucil-induced cytotoxicity by alpha-interferon and interleukin-2 in chronic lymphocytic leukemia Leukemia 1995 9: 1450–1455
Johnston JB, Daeninck P, Verburg L, Lee K, Williams G, Israels LG, Mowat MRA, Begleiter A . P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia Leuk Lymphoma 1997 26: 435–449
Cheson BD . Perspectives on purine analogues Hematol Cell Ther 1996 38: 109–116
Rummel M, Schenk M, Renner C, Reinhardt U, Knuth A, Hehlmann R, Hoelzer D, Mitrou PS, Bergmann L . Fludarabine and epirubicin in the treatment of CLL as first line therapy or in first relapse – results of a phase-II study Blood 1997 90: 530a
Bosch F, Perales M, Cobo F, Esteve J, Rafel M, Lopez-Guillermo A, Ribera JM, Campo E, Montserrat E . Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL) Blood 1997 90: 530a
Consoli U, El-Tounsi I, Sandoval A, Snell A, Kleine H-D, Brown W, Robinson JR, Di Raimondo F, Plunkett W, Andreeff M . Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia Blood 1998 91: 1742–1748
Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK . Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia J Exp Med 1993 177: 213–218
Rojas R, Roman J, Torres A, Ramirez R, Carracedo J, Lopez R, Garcia JM, Martin C, Pintado O . Inhibition of apoptotic cell death in B-CLL by interferon gamma correlates with clinical stage Leukemia 1996 10: 1782–1788
Menzel T, Rahman Z, Calleja E, White K, Wilson EL, Wieder R, Gabrilove J . Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine Blood 1996 87: 1056–1063
Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW . Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance Oncogene 1996 12: 1055–1062
Acknowledgements
This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG Schr 318/4-1). FS was supported by a research fellowship of the DFG (Schr 318/3-1). We gratefully acknowledge the helpful discussions with M Andreeff MD, PhD (MD Anderson Cancer Center, University of Texas) and with H Renz, MD (Charité, Virchow-University Hospital, Berlin). A Mohnhaupt PhD (Charité, Virchow-University Hospital, Berlin) provided invaluable help performing the statistical analyses.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Klein, A., Miera, O., Bauer, O. et al. Chemosensitivity of B cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair. Leukemia 14, 40–46 (2000). https://doi.org/10.1038/sj.leu.2401636
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401636
Keywords
This article is cited by
-
Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment
Experimental Hematology & Oncology (2021)
-
Evaluation of Caspase-9b and PP2Acα2 as potential biomarkers for chronic lymphocytic leukemia
Biomarker Research (2016)
-
The DNA repair complex Ku70/86 modulates Apaf1 expression upon DNA damage
Cell Death & Differentiation (2011)
-
DNA repair Ku proteins in gastric cancer cells and pancreatic acinar cells
Amino Acids (2008)
-
Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters
Medical Oncology (2008)